• Vaccine Name: ChAd63-MVA MSP1
• Target Pathogen: Plasmodium spp.
• Target Disease: Malaria
• Type: Recombinant vector vaccine
• Status: Clinical trial
• Host Species for Licensed Use: Human
• Antigen: MSP1: merozoite surface protein 1 of P.falciparum(Sheehy et al., 2011)
• MSP-1 from P. falciparum gene engineering:
  • Type: Recombinant protein preparation
  • Description: conserved blocks of P. falciparum MSP1 sequence and the sequence encoding 42-kDa C-terminus (MSP142) (Sheehy et al., 2011)
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)
• Description: Prime-boosting combination that use the same antigen but different vectors: ChAd63 MSP1 is the prime vaccination and MVA MSP1 is the booster. (Sheehy et al., 2011)

Human Response

• Host Strain: malaria-naive adults from Oxford area (Sheehy et al., 2011)
• Host age: 19-30 years(Sheehy et al., 2011)
• Host gender: 9 female, 7 male(Sheehy et al., 2011)
• Vaccination Protocol: Phase Ia, non-randomized study.
  Participants were separated into two groups: 1) Six volunteers received 5 × 10^9 viral particles ChAd63 MSP1 as primary vaccination, and four of these received 5 × 10^8 pfu MVA MSP1 as booster 56 days later. 2) 10 volunteers received 5 × 10^10 viral particles ChAd63 MSP1 as primary vaccination, and eight of these received 5 × 10^8 pfu MVA MSP1 as booster 56 days later. (Sheehy et al., 2011)
• Immune Response: Cellular: peak of IFN-γ SFC response at day 14, stronger response in higher dose group (2,785 versus 979 SFU/million PBMC). Responses contracted by day 56 and were maintained at day 90. After MVA MSP1: responses were boosted and maintained at high level at day 140 with significantly stronger response in higher dose group (1,640 versus 1,347 SFU/million PBMC). Both CD4+ and CD8+ responses were detectable after peptide restimulation on day 84.
  
  Humoral: peak of antibody responses against MSP119 at day 28, stronger response in higher dose group (53.1 versus 7.8 MSP1 AU). Responses contracted by day 56, and only responses in higher dose group were maintained at day 90. After MVA MSP1: responses were significantly boosted and reached peak at day 84, stronger response in higher dose group (4,266 versus 1,618 MSP1 AU). Response maintained at day 140, and higher dose group had stronger response. (Sheehy et al., 2011)
• Side Effects: Local: swelling, pruritus, warmth, erythema, and pain. Systematic: nausea, malaise, headache, fever, feverish, fatigue, arthralgia, and myalgia
  Most of the AEs were mild in severity and all resolved completely. (Sheehy et al., 2011)
• Challenge Protocol: Sporozoite malaria challenge 12-28 days post second vaccination. (Hill et al., 2009)